Printer Friendly

Israel : TEVA, LONZA to put an end to TL-JV.

After a strategic review, Teva Pharmaceutical Industries and Lonza have together decided to put an end to biologics joint venture, the Teva-Lonza Joint Venture (TL-JV).

Started in 2009 for the development, manufacturing and marketing of biosimilars, TL-JV will now break off advancing the individual strategies of both the firms.

This decision supports our ability to maintain a highly selective approach in our efforts to create a balanced portfolio of biosimilars, biobetters and innovative biologics that align with our overall portfolio and areas of disease focus, and by doing so better support our patients in these areas, said Teva CSO and global R&D president Dr Michael Hayden.

According to its biologics strategy, Teva is likely to build a balanced portfolio of biosimilars, biobetters and new biologics, while Lonza will concentrate on core expertise in contract manufacturing and cell line development and ceases investing in non-strategic areas.

With the discontinuation of the joint venture we will cease investing in areas that are not strategic to Lonza such as clinical developments and end product commercialization, said Lonza pharma and biotech market segment COO Dr Stephan Kutzer.

2013 Al Bawaba (

Provided by an company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jul 29, 2013
Previous Article:Ireland : Alexion Pharmaceuticals to Establish Global Supply Chain and Quality Operations in Ireland.
Next Article:Israel : Cabinet Approves Opening of Diplomatic Negotiations between Israel and the Palestinians in Accordance with PM Netanyahu's Statement on the...

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters